Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Key facts

Sponsor

Nanjing University School of Medicine

Principal Investigator

Zheng Tang, Doctor

Nanjing University School of Medicine

Intervention

tripterygium wilfordii (TW)(drug)

Enrollment

90 enrolled

Eligibility

18-60 years · All sexes

Timeline

2009 – 2011

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07571746
  A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
  AstraZeneca
• RECRUITINGPHASE2NCT07146906
  A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
  Novartis Pharmaceuticals
• RECRUITINGPHASE1, PHASE2NCT07375758
  A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
  Beijing Mabworks Biotech Co., Ltd.
• RECRUITINGPHASE1, PHASE2NCT07182227
  PS-002 for the Treatment of IgA Nephropathy in Adults
  Purespring Therapeutics Limited
• RECRUITINGPHASE3NCT07390123
  Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
  Haisco Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06994845
  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
  Novartis Pharmaceuticals
• RECRUITINGPHASE2NCT07305974
  A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
  Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
• RECRUITINGPHASE4NCT07030894
  Nefecon and Ambrisentan in IgA Nephropathy
  The First Hospital of Jilin University

See all trials for IgA Nephropathy →